MAPT and Classical progressive supranuclear palsy: OGA inhibitors have recently entered early clinical trials for the treatment of Progressive Supranuclear Palsy [163] as O-GlcNAcylation of Tau blocks the pathological effects of phosphorylation and aggregation of Tau [76].